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Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor
antagonist. Two randomised blinded trials were conducted to assess the effect of gastrazole in advanced pancreatic cancer. Patients
with biopsy-proven, inoperable pancreatic carcinoma were recruited. Trial A compared protracted venous infusion (PVI) gastrazole
with PVI placebo, whereas trial B compared PVI gastrazole with PVI fluorouracil (5-FU). Eighteen patients were randomised in trial A.
Gastrazole produced significantly better survival compared to placebo (median 7.9 months vs 4.5 months; 1-year survival: 33 vs 11%,
respectively; log rank P¼0.02). No difference in toxicity was seen between gastrazole and placebo, except central venous catheter
and pump complications. Ninety-eight patients were randomised in trial B. No significant survival difference was detected between
gastrazole and 5-FU (median: 3.6 vs 4.2 months; 1-year survival: 13.2 vs 26.2%, respectively; log rank P¼0.42). Toxicity of gastrazole
was mild with significantly less diarrhoea (P¼0.03), stomatitis (Po0.001) and hand– foot syndrome (Po0.001) compared to 5-FU.
Quality of life (QoL) assessment showed similar QoL between gastrazole and 5-FU at baseline and no significant differences occurred
with treatment either between arms or within arms. Compared to placebo, patients with advanced pancreatic cancer treated with
gastrazole appeared to live longer, albeit in a very small trial and will require confirmation with large-scale randomised data. However,
it did not produce survival advantage over PVI 5-FU. Lack of toxicity for gastrazole may allow its combination with cytotoxic drugs.
British Journal of Cancer (2006) 94, 1107–1115. doi:10.1038/sj.bjc.6603058 www.bjcancer.com
Published online 4 April 2006
& 2006 Cancer Research UK
Keywords: gastrin; pancreatic cancer; fluorouracil; placebo
                                                       
Pancreatic cancer accounted for approximately 232300 cases
and 227000 deaths in 2002 worldwide (Parkin et al, 2005).
It is associated with poor prognosis with a 5-year survival
of o5%. Radical surgery is the only curative option, but only
10–15% of reported patients undergo potentially curative resec-
tion (Neoptolemos et al, 2003). For the remaining patients,
palliative chemotherapy has been shown to improve survival and
quality of life (QoL) compared to best supportive care in patients
with good performance status (PS), although the survival gain was
modest (Glimelius et al, 1996; Fung et al, 2003).
Gemcitabine is regarded as the current standard of care for
untreated patients with advanced pancreatic cancer. The pivotal
randomised controlled trial (RCT) compared gemcitabine with
fluorouracil (5-FU) given over 30min and showed that gemcita-
bine had a superior survival and clinical benefit response
compared to short infusion 5-FU (Burris et al, 1997). Based on
these data, the National Institute of Clinical Excellence (NICE) in
the United Kingdom recommended in 2001 the use of gemcitabine
monotherapy for patients with advanced pancreatic cancer. Since
the pivotal study, over 5000 patients have been randomised in
phase III trials comparing gemcitabine alone with other cytotoxic
and biological agents either alone or in combination with
gemcitabine. Gemcitabine monotherapy has consistently produced
a median survival of 5–7 months and 1-year survival rate of 19–
25% in these trials. Up until 2005, none of the drug combinations
had shown superior results over gemcitabine monotherapy.
However, in a previously published RCT, protracted venous
infusion (PVI) 5-FU produced a median survival of 5.1 months
and 1-year survival of 23.5% (Maisey et al, 2002). Although
there has not been any direct comparison between PVI 5-FU
and gemcitabine, the similar survival achieved by PVI 5-FU and
gemcitabine provides the rationale for the use of PVI 5-FU as a
control arm in phase III studies.
In view of the poor prognosis in advanced pancreatic cancer,
novel treatment strategies are required. Gastrin has been shown to
be a growth stimulator in human pancreatic adenocarcinoma cells.
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sSeveral studies have reported the expression of cholecystokinin
(CCK) 2/gastrin receptors (both classical and an intron 4 splice
variant) in human pancreatic cancer tissue (Clerc et al, 2002;
Smith et al, 2002, 2004). It appears that gastrin stimulates growth
of human pancreatic cancer by a receptor-mediated process and a
unique CCK receptor exists in human pancreatic cancer that
functions in growth, but is not found in normal human pancreas
(Smith et al, 2002). Gastrazole (JB 95008, James Black Foundation,
London) is a novel, potent and selective CCK2/gastrin receptor
antagonist. In vitro and in vivo studies have demonstrated
the inhibition of gastrin-stimulated growth of pancreatic cancer
by gastrazole (Roberts et al, 2002). Because of poor (o0.1%) oral
bioavailability, the drug requires administration by PVI via a
central venous catheter. A pilot study was conducted in 10 patients
with advanced, inoperable pancreatic cancer and their survival was
compared with historical controls not undergoing active treatment
(Heneghan et al, 2001). A significant improvement in survival was
seen with gastrazole (median 7.5 months in gastrazole arm vs 3.3
months in historical control arm; P¼0.03). No significant adverse
events were attributed to gastrazole.
To evaluate the therapeutic effect of gastrazole in patients
with advanced pancreatic cancer, two RCTs were conducted
and reported here. The first study compared PVI gastrazole
with placebo and was performed to assess whether the apparent
survival advantage seen in the pilot study was not secondary
to the additional care and attention given to patients within
a clinical trial setting. In addition, despite chemotherapy,
patients with advanced pancreatic cancer have a very modest
survival, and for this reason, a placebo-controlled trial was
considered ethically acceptable by investigators at University
College Hospitals, London. The second study compared PVI
gastrazole with PVI 5-FU.
PATIENTS AND METHODS
Study design
Both studies were designed to assess whether gastrazole would
improve overall survival in patients with advanced pancreatic
cancer. Trial A was a double-blinded, placebo-controlled trial in
which patients were randomly allocated to receive PVI gastrazole
or PVI saline/ethanol. This study was conducted in a single
centre and was approved by its institutional research and ethics
committee. Trial B was a single blinded trial in which patients were
randomly allocated to receive PVI gastrazole or PVI 5-FU. The
appearance of the drug solution (5-FU or gastrazole), dosing and
all interventions were indistinguishable and were blinded to the
patients. However, because of the necessary medical interventions
to potential toxicity, drug treatment was not blinded to medical
staff. This study was conducted in six centres in the United
Kingdom and was approved by the multicentre research and ethics
committee. Signed, written informed consent was obtained from
each patient participating in both studies.
The primary end point in both studies was overall survival.
Secondary end points included QoL, objective radiological
response, toxicity, pain and analgesia requirement, weight changes
and changes in serum tumour marker levels (carbohydrate antigen
(CA)19-9).
Patient eligibility
Both studies had broadly similar eligibility criteria which were:
histologically or cytologically confirmed locally advanced or
metastatic carcinoma of the pancreas not amenable to surgical
resection or radical radiotherapy; aged 18 years old or more,
adequate bone marrow, liver and renal functions with platelet
4100 10
9l
 1, white blood cell 43 10
9l
 1, neutrophil
41.5 10
9l
 1, bilirubin o30mmoll
 1 (in trial B only), serum
creatinine below upper limit of institutional normal range; Eastern
Cooperative Oncology Group (ECOG) PS 0–2 or Karnofsky PS
X60%; no previous cytotoxic agent or prior radiotherapy; no
significant cardiac history or alcohol abuse and life expectancy of
43 months.
Patient randomisation
In trial A, details of all eligible patients were forwarded to a
company, independent of the investigators and sponsors, who
performed the randomisation based on a minimisation algorithm
stratifying for tumour size (o3cmorX3cm), presence or absence
of metastases, type of intervention to palliate obstructive jaundice
and/or duodenal obstruction (surgical or nonsurgical), PS, age,
serum albumin and C-reactive protein. Patients were randomly
assigned to each treatment arm on a 1:1 basis. In trial B, details
of all eligible patients were forwarded to the data manager’s
office based at the Royal Marsden Hospital, Sutton. Eligibility
criteria were verified and patients were randomly assigned to each
treatment arm on a 1:1 basis according to a computer-generated
randomisation code at an independent office. Randomisation was
stratified by treatment centre, PS and presence or absence of
metastases.
Pretreatment evaluation, assessment during treatment and
follow-up
Baseline evaluation included a complete medical history and
physical examination, full blood count and serum biochemistry
including electrolytes, liver and renal function tests, CA19-9,
electrocardiogram (ECG), chest X-ray (CXR) and computed tomo-
graphy (CT) of chest, abdomen and pelvis. Histological samples
were reviewed by the local histopathologists and were classified
into well-, moderately or poorly differentiated carcinoma. Baseline
performance status, pain assessment and analgesia requirement
and weight were assessed. Pain was assessed using Memorial Pain
Assessment card. Quality of life was assessed using the European
Organisation for Research and Treatment of Cancer core QoL
questionnaire (EORTC QLQ c30).
During treatment, performance status was reassessed at each
clinic visit where pain and analgesic assessment were made every 3
weeks. CA19-9, body weight and QoL were reassessed every 6
weeks. Repeat radiological assessment was made every 12 weeks. A
repeat ECG was recorded after 1 week and 6 weeks of treatment
only.
Treatment
In trial A, for patients assigned to placebo, a set volume
was withdrawn from a standard 0.9% sterile saline solution
and an equivalent volume of absolute ethanol was replaced to
achieve a concentration of 35% vv
 1. Patients randomly assigned
to gastrazole received gastrazole at 500mgday
 1 dissolved in
saline/ethanol administered as a continuous infusion via a double
lumen central venous Hickman catheter. A unit dose of
500mgday
 1 was used which was equivalent to 0.3mgkg
 1h
 1
for a 70kg patient. This dose produced the highest plasma
concentration that could be accommodated based on toxicity
testing producing a receptor occupancy of 495% and was well
tolerated in the pilot study. In trial B, patients randomly assigned
to receive gastrazole would receive gastrazole at 500mgday
 1
identical to patients in trial A. Those patients assigned to
5-FU would receive 5-FU at 300mgm
 2day
 1 administered as a
continuous infusion via a central venous catheter. No routine
antiemetic medications were given. Warfarin (1mgday
 1 orally)
was administered throughout the treatment to prevent catheter
thrombosis in all patients.
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intolerable toxicity, whereas patients in trial B continued treatment
until evidence of radiological disease progression. All patients were
followed up till death.
Dose modifications
Toxicity was assessed according to National Cancer Institute-
Common Toxicity Criteria version 2. If stomatitis, hand–foot
syndrome or diarrhoea related to 5-FU developed, 50, 100 and
150mgm
 2 dose reductions in 5-FU were made if grades 2, 3 and 4
toxicities developed, respectively. No specific dose modification
was recommended for gastrazole as no specific toxicity was
anticipated.
Evaluation of response
Radiological tumour response was evaluated according to World
Health Organisation (WHO) Criteria (Miller et al, 1981). Complete
response (CR) was defined as the complete disappearance of all
measurable lesions, without the appearance of new lesion(s).
Partial response (PR) was defined as a reduction of bidimensional
lesions by X50% of the sum of the products of the largest
perpendicular diameters of each measurable lesion and no
progression in other lesions or the appearance of any new lesions.
Stable disease (SD) was defined as a o50% reduction of tumour
volume or a o25% increase of the volume of one or more
measurable lesions, with no new lesions. Progressive disease (PD)
was defined as an increase of X25% of the size of at least one
bidimensionally measurable lesion, the appearance of new
lesion(s), and/or the onset of ascites or pleural effusion with
cytological confirmation.
Role of the funding source
The investigators and representatives from James Black Founda-
tion designed the study. The data were collected and analysed by
medical and statistical representatives from Royal Marsden
Hospital and James Black Foundation. All the investigators had
access to the primary data and participated in writing the
manuscript. All the participating institutions received grant
support from James Black Foundation for conducting the study.
Statistical considerations
In trial A, with a planned 200 patients to be randomised, it was
expected that a 50% increase in median survival (from 90 days in
the placebo arm to 135 days in the gastrazole arm) could be
detected with at least 80% power (two-sided alpha¼5%). In trial
B, with a planned 172 patients to be randomised, 1-year survival
improvement from 25% (5-FU arm) to 45% (gastrazole) could be
detected with at least 80% power (two-sided alpha¼5%).
Although both trials were planned at the same time, trial B
commenced in June 1999 and trial A commenced a year later due
to a delay in obtaining research and ethical committee approval.
However, the accrual was slow especially towards the latter part of
the trial period following the publication of NICE guidelines in
2001 when gemcitabine has become increasingly accepted as the
standard treatment in the United Kingdom. In February 2003, the
principal investigators in conjunction with the sponsor decided to
suspend recruitment into both trials.
Tumour response rates and toxicities between treatment arms
were compared using the w
2 test with Fisher’s exact test used where
appropriate. Serum CA19-9 level was not a normally distributed
variable, thus log normalisation of CA19-9 was performed to allow
parametric statistical analysis. Overall survival (OS) from rando-
misation was calculated from the date of randomisation into the
study to the date of death from any cause. Progression-free
survival (PFS) was calculated from the date of randomisation into
the study to the date of either disease progression or death. Both
OS and PFS were estimated using Kaplan–Meier method (Kaplan
and Meier, 1958) and were compared between treatment arms
using log rank test (Peto and Peto, 1972). Hazard ratios (HR) were
quoted with the control arms (placebo and 5-FU) set at 1.
All analyses were performed on an intention-to-treat basis. The
primary end points were updated in June 2004.
RESULTS
Between June 2000 and February 2003, 18 patients were
randomised in trial A. Between June 1999 and November 2002,
98 patients were randomised in trial B. Three patients were
ineligible in trial B due to elevated serum creatinine at baseline
(n¼1), alcohol abuse (n¼1) and no diagnosis of pancreatic
cancer (n¼1). Figure 1 shows the trial profiles. Thus, 95 patients
were analysed according to an intention-to-treat basis. Table 1
shows the patients’ characteristics of both trials.
Antitumour effect
As expected, objective tumour responses were infrequent in all
trial arms. No objective responses occurred in either arm in trial A.
Two partial responses (5%) were seen within the 5-FU arm in trial
B (Table 2). No statistically significant difference was seen between
gastrazole and 5-FU (P¼0.60).
At the time of analysis, all patients in trial A and 92 of the 95
(97%) patients in trial B had died. Figures 2 and 3 show the overall
survival by treatment arms in trials A and B, respectively. In
trial A, gastrazole was associated with a statistically significant
prolonged survival (HR: 0.29; 95% confidence interval (CI): 0.10–
0.85; log rank P¼0.02). The median survival for gastrazole and
placebo were 7.9 vs 4.5 months and the corresponding 1-year
survival rates for gastrazole and placebo were 33.3% (95% CI: 7.8–
62.3%) and 11.1% (95% CI: 0–38.8%), respectively. The cause of
death was due to carcinoma in 17 (94%) patients.
There was no statistically significant difference in OS between
gastrazole and 5-FU (HR: 1.19; 95% CI: 0.79–1.78; log rank
P¼0.42). The median survival for gastrazole and 5-FU was 3.6
Trial A
N=18 
Placebo
N=9
Gastrazole
N=9 
Trial B
N=98
5-FU
N=42
Gastrazole
N=53 
Ineligible patients
N=3
Figure 1 Trial profile.
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smonths vs 4.2 months, respectively, and the 1-year survival rates
for gastrazole and 5-FU was 13.2% (95% CI: 5.8–23.7%) vs 26.2%
(95% CI: 14.1–40%). The causes of death were due to carcinoma in
86 (93%) patients. In trials A and B, the 60-day all-cause mortality
rates were 0 and 22.1% (95% CI: 15–31.9%; gastrazole: 19%, 5-FU:
22.6%), respectively.
There were no differences in PFS between gastrazole and
placebo (log rank P¼0.56), nor between gastrazole and 5-FU (log
rank P¼0.18). The median PFS for gastrazole and 5-FU was 2.3
and 2.7 months, respectively.
Toxicity
In trial A, toxicity was mild in both arms. Grade 3 adverse events
were reported for eight patients in both the gastrazole and placebo
arms and grade 4 adverse events occurred in three patients
receiving gastrazole and none in those receiving placebo. However,
the majority of these adverse events were considered to be disease-
related rather than treatment-related. One patient developed
grade 3 anaemia in gastrazole arm due to gastrointestinal bleeding
unrelated to treatment, but no grade 3 or 4 neutropenia and
thrombocytopenia were observed in the gastrazole arm. Deep
venous thrombosis occurred in two patients in the gastrazole arm
and one patient in the placebo arm. Table 3 shows the incidence of
Hickman line and pump device complications by treatment arm
in both trials. On visual inspection, more patients developed
complications in the gastrazole arm compared to placebo arm, but
no formal statistical comparisons were performed due to small
number of patients in each group.
Table 4 shows the grades 3 and 4 toxicities in trial B. Toxicities
commonly related to protracted administration of fluoropyrimi-
dines such as hand–foot syndrome, stomatitis and diarrhoea were
all more frequent in the 5-FU arm. There were no significant
differences in the incidences of Hickman line complications
Table 1 Baseline characteristics
Characteristics Gastrazole Placebo
Trial A
Number of patients 9 9
Median age (range) 57 (44–75) 67 (55–78)
Male 6 (67%) 7 (78%)
Karnofsky performance status
90–100% 2 (22%) 3 (33%)
70–80% 6 (67%) 6 (67%)
Unknown 1 (11%) 0 (0%)
Metastatic disease 2 (22%) 4 (44%)
Tumour differentiation
Well 0 (0%) 0 (0%)
Moderately 3 (33%) 0 (0%)
Poorly 6 (67%) 8 (89%)
Undetermined 0 (0%) 1 (11%)
Tumour subsites
Head 8 (89%) 7 (78%)
Body 1 (11%) 1 (11%)
Tail 0 (0%) 1 (11%)
Characteristics Gastrazole 5-FU
Trial B
Number of patients 53 42
Median age (range) 64 (35–78) 66 (38–82)
Male 27 (51%) 24 (57%)
ECOG performance status
0 12 (23%) 7 (17%)
1 34 (64%) 26 (62%)
2 6 (11%) 8 (19%)
Unknown 1 (2%) 1 (2%)
Metastatic disease 35 (67%) 24 (59%)
Tumour differentiation
Well 3 (6%) 4 (10%)
Moderately 24 (45%) 15 (36%)
Moderately-poorly 1 (2%) 1 (2%)
Poorly 12 (23%) 15 (36%)
Undetermined 3 (25%) 7 (17%)
Tumour subsites
Head 40 (75%) 36 (86%)
Head+body 3 (6%) 1 (2%)
Body 3 (6%) 3 (7%)
Body+tail 2 (4%) 0 (0%)
Tail 2 (4%) 1 (2%)
Missing 3 (6%) 1 (2%)
ECOG¼Eastern Cooperative Oncology Group; 5-FU¼5-fluorouracil.
Table 2 Objective tumour response in trial B
Gastrazole
(n¼53)
5-FU
(n¼42) P
Complete response 0 (0%) 0 (0%)
Partial response 0 (0%) 2 (5%)
Stable disease 15 (29%) 12 (29%)
Progressive disease 38 (71%) 28 (66%)
Objective response rate (95%
confidence interval)
0% 5% (1–16%) 0.60
5-FU¼5-fluorouracil.
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sbetween the two arms (P¼0.07). Treatment-related mortality
occurred in one patient in the 5-FU arm.
Quality of life and clinical benefit response
In trial B, the compliance in completing QoL questionnaires was
remarkably good considering the multicentre nature and the poor
prognosis of the patients with less than 30% attrition rate at 6 and
12 weeks post randomisation. Table 5 shows the QoL scores in trial
B. There were no significant differences in the QoL functional
scores at baseline. Functional QoL was maintained in both
arms during treatment with no significant differences from
baseline. Patients randomised to gastrazole had significantly worse
dyspnoea at baseline (P¼0.004), but all other symptom scores
were similar in both arms.
In trial B, using the visual analogue scale and pain description
score, no significant differences was seen with pain between the
two arms both at baseline and during treatment. Figure 4 shows
these VAS scores graphically. There was no difference in the
baseline weight in both arms. During treatment, there was
significant weight loss in the gastrazole arm compared to baseline
(Po0.01 at weeks 6, 12 and 18), although there was no significant
difference between the treatment arms. Figure 5 shows the change
in weight compared to baseline. There were no significant
differences in performance status between the two arms either at
baseline (P¼0.27) or during treatment (P¼0.55, 0.68 and 0.15 at
weeks 6, 12 and 18, respectively).
In trial A, there did not appear to be any difference in the
baseline serum CA19-9 levels between gastrazole and placebo, but
a much smaller increase in median serum CA19-9 levels was
observed with gastrazole compared to placebo during treatment.
However, no formal statistical testing was performed due to small
sample size. Table 6 shows the serum CA19-9 levels in trial A. In
trial B, there was no significant difference in the median serum
CA19-9 level at baseline (P¼0.54). Patients in 5-FU arm had a
significant reduction in the CA19-9 levels after log normalisation
(Po0.01 at weeks 6, 12 and 18) compared to patients in the
gastrazole arm. The serum bilirubin level during the same time
periods were also extracted and found to have no differences
between the two arms at baseline or throughout the treatment
periods. Figure 6 shows the difference in log CA19-9 level
compared to baseline. Using the antilog of the log CA19-9
differences, it gave an indication of the proportional difference
in the CA19-9 level from baseline. At 6 weeks, patients in the 5-FU
arm experienced a 63% decrease in the CA19-9 level compared to
baseline, whereas patients in the gastrazole arm experienced a 2.46
times increase (Po0.01).
DISCUSSION
Advanced pancreatic cancer has attracted much research effort in
recent years due to its poor outcome and lack of effective
treatment. Newer cytotoxic agents such as premetrexed (Oettle
et al, 2005), exatecan (Cheverton et al, 2004; O’ Reilly et al, 2004),
oxaliplatin (Louvet et al, 2005), irinotecan (Rocha Lima et al, 2004)
and novel agents targeting matrix metalloproteinase (Bramhall
et al, 2001, 2002; Moore et al, 2003), and farnesyltransferase (Van
Cutsem et al, 2004) had all entered phase III testing either alone or
in combination with gemcitabine – the current standard of care.
Yet despite these efforts, none of these drugs have shown an OS
advantage over gemcitabine monotherapy.
Targeting gastrin-induced cancer growth represents a novel
therapeutic target for pancreatic cancer. In vitro, gastrazole alone
had a significant inhibitory effect upon the gastrin-stimulated
growth of BxPC-3 cells (unpublished data). The first pilot study
suggested early promising survival compared to historical control
(Heneghan et al, 2001) and this coupled with lack of toxicity
of gastrazole led to the design of the two randomised studies
described in this article. Although a recent meta-analysis
confirmed the survival benefit for patients treated with 5-FU-
based treatment compared to those who received supportive care
alone (HR: 0.53; 95% CI: 0.44–0.63; Po0.0001) (Fung et al, 2003),
the absolute survival gain was still very modest, thus a placebo-
controlled randomised study was considered ethical in trial A.
Indeed, another randomised placebo-controlled study was recently
reported evaluating another gastrin-targeted strategy using
G17DT, a gastrin immunogen inducing neutralising antibodies to
gastrin. A borderline significant survival benefit was seen with
G17DT compared to placebo (median survival 150 vs 83 days;
Wilcoxon P¼0.047), although there was a lower incidence of
metastatic stage IV disease in the G17DT arm (73 vs 84%,
respectively) (Gilliam et al, 2004). However, when G17DT was
combined with gemcitabine in an RCT of 383 patients, the
combination did not produce a survival advantage over gemcita-
bine alone (P¼0.1) (Shapiro et al, 2005). In our trial A, gastrazole
was associated with a longer survival compared to placebo
(P¼0.02). However, of note, there was a higher proportion of
locally advanced disease in the gastrazole arm, although survival
was still better with gastrazole in the subgroup of patients with
locally advanced disease only compared to placebo (data not
shown). The relative long survival, seen with both treatment arms
in trial A was due to several reasons: firstly, the trial population
was mainly consisting of locally advanced disease; secondly, this
was a single institution study; thirdly and probably most
Table 3 Hickman line and pump device complications by treatment
arms
Gastrazole (n¼9) Placebo (n¼9)
Trial A
Infection (%) 56 22
Haematoma (%) 11 22
Device breakage (%) 33 22
Device leakage (%) 33 22
Device failure NOS (%) 78 33
Gastrazole (n¼53) 5-FU (n¼42)
Trial B
Infection (%) 21 19
Thrombosis (%) 6 0
Pneumothorax (%) 4 2
Blocked line (%) 25 2
Damaged line (%) 2 2
Any complications (%) 55 36
NOS¼not otherwise specified; 5-FU¼5-fluorouracil. Category coding for Hickman
line and pump device complications was different between trials A and B.
Table 4 Grades 3 and 4 toxicities in trial B
Gastrazole
(n¼53) (%)
5-FU (n¼42)
(%)
P-values for
trend
Diarrhoea 2 7 0.03
Stomatitis 0 5 o0.001
Hand foot syndrome 0 2 o0.001
Nausea 8 5 0.76
Vomiting 9 7 0.64
Lethargy 36 33 0.95
Infection 15 10 0.34
Anaemia 6 16 0.72
Thrombocytopenia 2 3 0.82
Neutropenia 2 3 0.14
5-FU¼5-fluorouracil.
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than until disease progression in this protocol. If gastrazole indeed
had a tumour growth inhibitory effect, continuing treatment after
radiological definition of disease progression might still had had
some degree of antitumour effect, albeit small, leading to a more
prolonged survival in trial A. The above reasons might have also
Table 5 Quality of life scores in trial B
Baseline 6 weeks 12 weeks
Mean s.d. P-value Mean Diff from base P-value Mean Diff from base P-value
Functioning scales
Physical
Gastrazole 73.6 21.1 0.97 66.0  6.16 0.34 66.6  6.75 0.39
5-FU 73.3 21.3 74.1  3.92 75.4  0.47
Role
Gastrazole 53.6 35.7 0.30 51.9  3.48 0.38 58.8 2.00 0.43
5-FU 63.1 27.8 32.2  12.12 61.4  10.00
Emotional
Gastrazole 71.1 22.4 0.76 70.6  0.12 0.64 65.5  0.80 0.93
5-FU 71.9 23.4 77.8 3.25 75.5 2.20
Cognitive
Gastrazole 78.4 19.5 0.87 73.9 0 0.96 75.1  5.53 0.18
5-FU 78.9 19.2 79.4  0.52 83.3 4.25
Social
Gastrazole 62.4 33.5 0.55 54.3  1.88 0.08 54.2  16.50 0.33
5-FU 69.0 25.5 56.3  15.52 29.7  5.25
Global
Gastrazole 61.4 21.9 0.42 54.5  7.35 0.35 56.2  8.36 0.22
5-FU 57.05 21.0 61.2  0.33 67.7 2.00
Symptom scales
Fatigue
Gastrazole 43.3 27.3 0.98 48.6 5.92 0.95 55.0 17.64 0.16
5-FU 42.8 23.1 43.6 6.54 38.5 4.14
N&V
Gastrazole 17.1 23.6 0.94 21.5 5.00 0.36 22.0 6.50 0.37
5-FU 19.3 25.8 15.6  2.36 15.6  2.27
Pain
Gastrazole 34.9 28.5 0.82 42.2 2.67 0.61 45.7 4.86 0.16
5-FU 35.6 28.5 33.9 1.27 22.9  4.79
Dyspnoea
Gastrazole 21.2 25.0 o0.01 25.8 6.68 0.51 29.6 12.56 0.07
5-FU 7.0 15.8 9.5 4.93 4.1  2.20
Sleep disturbance
Gastrazole 34.8 28.8 0.46 31.0 1.22 0.15 22.7  5.56 0.33
5-FU 31.6 34.7 25.4  10.45 10.3 22.27
Appetite
Gastrazole 39.9 40.6 0.67 50.6 11.26 0.99 50.8 12.94 0.09
5-FU 36.7 39.6 42.2 9.24 27.0  4.53
Constipation
Gastrazole 24.2 34.0 0.24 19.8 1.27 0.28 14.6  9.0 0.36
5-FU 31.6 32.9 17.8  15.0 13.7 0
Diarrhoea
Gastrazole 15.1 25.4 0.75 17.3 1.27 0.81 26.7 11.13 0.48
5-FU 17.5 27.7 20.72 2.43 21.5  0.06
Financial
Gastrazole 34.1 38.2 0.36 28.4  7.96 0.88 24.4  7.62 0.68
5-FU 27.9 38.1 25.6  3.54 23.5  10.38
N&V¼nausea and vomiting; s.d.¼standard deviation; Diff from base¼difference from baseline.
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compared to trial B.
Although gemcitabine has shown survival superiority over 5-FU
given over 30min (Burris et al, 1997), trial B has confirmed the
efficacy of PVI 5-FU in advanced pancreatic cancer to be similar to
gemcitabine. The 1-year survival rates for PVI 5-FU in this study
(26%) and in a previous study (24%) (Maisey et al, 2002) were
comparable to gemcitabine (19–25%). Therefore, the use of PVI 5-
FU as the control arm in this study was justified. Furthermore,
QoL was maintained during treatment, which was an achieve-
ment considering the rapid deterioration of cancer-related
symptoms seen commonly with advanced pancreatic cancer.
Whereas the addition of bolus 5-FU to gemcitabine did not
significantly improve the efficacy of gemcitabine alone (Berlin
et al, 2002), PVI 5-FU or oral fluoropyrimidines may be a more
efficacious partner to gemcitabine. Indeed, two European rando-
mised studies evaluated the role of capecitabine in combination
with gemcitabine. Both of which showed an improved efficacy with
gemcitabine/capecitabine combination with the UK study showing
statistically superior survival advantage over gemcitabine alone
(P¼0.026) (Cunningham et al, 2005). However, more recently,
erlotinib, an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor, plus gemcitabine has also been reported to
improve survival over gemcitabine alone (Moore et al, 2005).
In trial B, there was no significant difference in survival between
gastrazole and 5-FU. However, because of poor accrual, the study
was underpowered to show the originally proposed survival
differences between the treatment and there was a hint towards
better survival with PVI 5-FU. Nevertheless, no differences in QoL,
symptom and clinical benefit were seen between the arms. Clinical
benefit response is a composite measure of pain, analgesic use,
performance status and weight loss that has been increasingly
incorporated into clinical trials in metastatic pancreatic cancer.
There were no significant differences in pain perception, PS and
weight during treatment between the two arms. In conjunction
with trial A, these data would suggest that gastrazole is biologically
active. Furthermore, gastrazole was not associated with any major
toxicity, and most adverse events observed during the trial were
probably related to the underlying pancreatic cancer, except an
increase in Hickman line and delivery device complications.
Combination of cytotoxic agents with gastrazole either concomi-
tantly or sequentially would be a feasible treatment.
Serial CA19-9 measurements have been shown to predict
survival in patients treated with gemcitabine-based chemotherapy
(Stemmler et al, 2003; Ziske et al, 2003) and fluorouracil-based
chemoradiation (Micke et al, 2003). More recently, in a cohort of
154 patients treated with either PVI 5-FU, gemcitabine with or
without capecitabine, patients with low baseline CA19-9 (HR: 0.56,
P¼0.0004) or 20% decrease from baseline with treatment (HR:
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Table 6 Serum CA19-9 in trial A
Gastrazole
(kUl
 1)
Number of
patients with
measurement
Placebo
(kUl
 1)
Number of
patient with
measurement
Baseline median
level
312 8 403 9
Change from baseline median
At 6 weeks 21 8 913 9
At 12 weeks 594 9 3234 9
At 18 weeks 739 8 50533 4
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s0.53; P¼0.019) have been shown to have a superior survival
(Maisey et al, 2005). CA19-9 may serve as an early indication of
treatment efficacy with cytotoxic drugs, but interpretation of
CA19-9 kinetics is more complex with other molecular targeted
drugs. In advanced pancreatic cancer trials of marimastat, a matrix
metalloproteinase inhibitor, patients with stable or falling CA19-9
level during treatment had a significantly better survival compared
to those with rising CA19-9 in one trial (Evans et al, 2001), but not
in the other (Rosemurgy et al, 1999). In our trial A, gastrazole
appeared to slow down the increase of CA19-9 levels compared to
placebo. In trial B, 5-FU was associated with a significant
proportional decrease in CA19-9 whereas gastrazole showed a
rising level with treatment, yet survival was not significantly
different between the two arms. Cytotoxic drugs causing cell
apoptosis might lead to a decrease in tumour CA19-9 secretion,
whereas gastrazole, by inhibiting tumour growth, might only arrest
CA19-9 increase. The relationship between CA19-9 and treatment
efficacy in pancreatic cancer will need further evaluation in large
randomised trials.
As gastrin is a growth stimulant, a strategy against gastrin such
as gastrazole is most likely to succeed in the settings of minimal
tumour burden such as maintenance therapy after cytotoxic
chemotherapy (although few drugs result in significant tumour
shrinkage in pancreatic cancer) or adjuvant treatment. The poor
oral bioavailability of gastrazole necessitating central venous
administration would not allow further clinical development of
chronic administration of gastrazole in these settings, but
availability of an oral gastrin receptor antagonist would facilitate
the evaluation of gastrin receptor blockade in minimal disease or
adjuvant settings. Moreover, the lack of serious side effects would
represent a great step forward compared to bolus 5-FU/leucovorin
as adjuvant treatment (Neoptolemos et al, 2004).
In conclusion, patients with advanced pancreatic cancer treated
with gastrin receptor blockade using gastrazole appeared to live
longer compared to placebo, albeit in a very small trial and will
require confirmation with large-scale randomised studies. However,
it did not produce survival advantage over PVI 5-FU. Lack of toxicity
for gastrazole may allow its combination with cytotoxic drugs.
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